EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series

Daiji Takamoto, Yu Shimada, Yuri Hasegawa, Takeaki Noguchi, Takashi Kawahara, Junichi Teranishi iD, Kazuhide Makiyama

IJU Case Reports · 2026-05 · 9 (3)

DOI: 10.1002/iju5.70183 ↗

Kurz gefasst

Fachartikel in der Zeitschrift IJU Case Reports, online erschienen am 27.04.2026. Verfasst von Daiji Takamoto und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cytomegalovirus (CMV) infection remains a common complication after kidney transplantation, particularly among high‐risk donor‐seropositive/recipient‐seronegative (D+/R−) recipients. Valganciclovir is the standard first‐line therapy; however, its use may be limited by hematological toxicity or impaired graft function. Maribavir is a recently approved antiviral agent with a distinct mechanism of action. Case Presentation We report four high‐risk kidney transplant recipients in whom maribavir was introduced because continued valganciclovir therapy was difficult owing to cytopenia or renal dysfunction. After switching therapy, CMV viral loads decreased in all cases, and hematological abnormalities improved following discontinuation of valganciclovir. One patient developed a drug‐induced skin eruption, while no other serious adverse events were observed. No CMV recurrence or graft dysfunction occurred during follow‐up.

Conclusion

These cases highlighted practical clinical considerations for managing CMV infection when standard antiviral therapy cannot be safely continued.

Autor:innen und Institutionen

  • Department of Urology and Renal Transplantation Yokohama City University Medical Center Yokohama Japan.
  • Department of Urology Yokohama City University Yokohama Japan.

ORCID-Profile: Junichi Teranishi

Zitieren

APA

Takamoto, D., Shimada, Y., Hasegawa, Y., Noguchi, T., Kawahara, T., Teranishi, J., & Makiyama, K. (2026). Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series. IJU Case Reports, 9(3). https://doi.org/10.1002/iju5.70183

Vancouver

Takamoto D, Shimada Y, Hasegawa Y, Noguchi T, Kawahara T, Teranishi J, et al. Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series. IJU Case Reports. 2026;9(3). doi:10.1002/iju5.70183

BibTeX
@article{Takamoto2026,
  author = {Takamoto, Daiji and Shimada, Yu and Hasegawa, Yuri and Noguchi, Takeaki and Kawahara, Takashi and Teranishi, Junichi and Makiyama, Kazuhide},
  title = {Maribavir for Cytomegalovirus Infection in High‐Risk Kidney Transplant Recipients: A Case Series},
  journal = {IJU Case Reports},
  year = {2026},
  volume = {9},
  number = {3},
  doi = {10.1002/iju5.70183}
}
Kostenlos starten →